REG - Ovoca Bio PLC - Change of Broker

Ovoca BioAnnouncement

13/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251113:nRSM3275Ha&default-theme=true

RNS Number : 3275H  Ovoca Bio PLC  13 November 2025

Ovoca Bio PLC

13 November 2025

 

Ovoca Bio plc

 

("Ovoca" or the "Company")

 

Change of Broker

 

Dublin, Ireland, 13 November 2025 - Ovoca Bio Plc announces, in anticipation
of completion of the acquisition of Tadeen International Limited as originally
announced on 7 May 2025, the appointment of CMC Markets UK Plc, trading as CMC
CapX, as broker to the Company with immediate effect. Beaumont Cornish Limited
will continue to act as the Company's Nominated Adviser.

 

End

 

For further information:

 

Ovoca Bio plc

Tim McCutcheon (Chief Executive Officer)

Tel +353 1 661 9819

info@ovocabio.com (mailto:info@ovocabio.com)

 

Beaumont Cornish Limited (Nominated Adviser)

James Biddle / Roland Cornish

Tel: +44 (0) 207 628 3396

 

CMC Markets UK Plc (Broker)

Douglas Crippen

Tel: +44 (0) 20 3003 8632

 

 

 

Nominated Adviser Statement

 

Beaumont Cornish Limited ("Beaumont Cornish"), is the Company's Nominated
Adviser and is authorised and regulated in the United Kingdom by the Financial
Conduct Authority. Beaumont Cornish's responsibilities as the Company's
Nominated Adviser, including a responsibility to advise and guide the Company
on its responsibilities under the AIM Rules for Companies and AIM Rules for
Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont
Cornish is not acting for and will not be responsible to any other person for
providing the protections afforded to customers of Beaumont Cornish nor for
advising them in relation to the transaction and arrangements described in the
announcement or any matter referred to in it.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPEAEFAFDESFAA



            Copyright 2019 Regulatory News Service, all rights reserved